Skip to Main Content

Advertisement

Skip Nav Destination

Ruben Mesa, MD: Momelotinib Non-Inferior to Ruxolitinib in Myelofibrosis

December 30, 2021
On location

Dr. Mesa reviews data from the SIMPLIFY 1 trial, which compared the novel JAK1/2 inhibitor momelotinib with ruxolintinib in patients with JAK inhibitor–naïve MF, in which momelotinib was non-inferior to ruxolitinib in splenic volume reduction, but failed to improve disease symptoms.

Advertisement

Connect with us:

CURRENT ISSUE
August 2022

Advertisement

Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement

X